Search results
Cara Therapeutics discontinues study on a neurological condition as drug fails
Reuters via Yahoo News· 1 hour ago(Reuters) - Cara Therapeutics said on Wednesday it will discontinue a mid-to-late stage study for a neurological condition that causes itching after its experimental
Study reveals unexpected mechanism of drug resistance in kidney cancer
Medical Xpress· 7 hours agoFor nearly two decades, how kidney cancer becomes resistant to rapalog drugs has baffled the scientific community. Published in the Proceedings of the National Academy of Sciences, the
Pfizer study finds Paxlovid ineffective against Long COVID despite federal research funds
22 WSBT South Bend· 11 hours agoA study on the antiviral drug Paxlovid released last week found the medication is not effective in...
Viridian (VRDN) Up 10% on Clinical Updates for Eye Disease Drug
Zacks via Yahoo Finance· 8 hours agoViridian (VRDN) intends to initiate two late-stage studies on its experimental thyroid eye disease ...
Eli Lilly's Potential Alzheimer’s Drug Clears a Big Hurdle
Time via Yahoo News· 1 day agoThe agency will now take the committee’s advice under consideration as it decides whether to approve...
The Donald Trump and Hunter Biden trials are over – the consequences will linger
USA TODAY via Yahoo News· 2 hours agoThe gun charges against Biden are rarely prosecuted. A Justice Department study in 1990 described...
Ultragenyx, Mereo drug reduces fractures in bone disorder study
BioPharma Dive via Yahoo Finance· 10 hours agoThe trial included people with a condition called osteogenesis imperfecta, which impacts bone...
The 'Impressive' Results That Sent Top 1% Avidity Biosciences To A Record
Investor's Business Daily· 1 hour agoAvidity Biosciences unveiled "impressive" results from a study of its treatment for a rare form of...
Avidity drug for muscular dystrophy shows promise; Syntis takes new approach to weight loss
BioPharma Dive via Yahoo Finance· 10 hours agoStudy results indicated Avidity’s medicine muted target genes. Elsewhere, Syntis revealed obesity ...
Pfizer Lingers Near 11-Year Low Despite Promising Cancer Drug Updates — Is It A Sell?
Investor's Business Daily· 4 hours agoDespite a bevy of promising updates for its cancer treatments, Pfizer stock remains trapped below a...